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 Abstract 
Introduction: Immune Checkpoint Inhibitors (ICIs) are antitumor drugs associated with a number of 
serious immune-related adverse events (IRAEs). ICIs enhance anti-tumor immunity, thereby  energized  
patient's immune system to fight cancer. IRAEs may affect functions of various organs, including heart, 
and may lead to morbidity and, to some  extent  mortality. Left ventricle (LV) myocarditis with 
dysfunction is a known side effect of this class of drugs. However, right ventricle (RV) myocarditis and 
pulmonary vasculitis are an unknown entity and has not been previously reported.  Here, we present the 
first case of  IRAEs causing selective RV involvement with dysfunctions, attributed to immune 
checkpoint inhibitors described till date in medical literature. 
Presentation of Case: A 58-year male presented  with history of low-grade fever and  weight loss. On 
palpation, he had diffuse cervical lymphadenopathy. Histopathology evaluation of  lymph node revealed  
metastatic lesions of Renal Cell Carcinoma (RCC). 
Conclusion: Fatal cardiovascular adverse events can occur as a side effect of ICI. The combination of RV 
myocarditis with progressive pulmonary hypertension is fatal. Treatment with high dose corticosteroids 
and immunomodulators may help in patient survival. Physicians treating patients with ICIs should be 
aware of their lethal cardiotoxic side effects  to reduce adverse cardiac outcomes. Because the number of 
patients exposed to this new immune therapy is expected to increase remarkably in the near future, our 
study encourages further work to define guidelines for cardiovascular monitoring and management.  
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Introduction 
 The development of immunotherapies in oncology over the past decade has revolutionised 
the management of advanced stage malignancies [1, 2]. The forefront of immunotherapy is represented 
by immune checkpoint inhibitors (ICIs), which inhibit molecules like monoclonal antibodies (mAbs) 
targeting ICIs {(e.g.  cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death-
1 protein (PD-1) and its programmed cell death ligand-1 (PD-L1) and 2 (PD-L2)}. These ICIs have 
shown success in the treatment of solid and   haematological tumours [2].  
 ICIs have transformed the treatment of various malignancies such as metastatic melanoma, 
bladder cancer, renal cancer, and non–small cell lung carcinoma (NSCLC) [1]. Ipilimumab, which 
targets CTLA-4 and  PD-1 (nivolumab, pembrolizumab and cemiplimab) and PD-L1 (atezolizumab, 
durvalumab, avelumab and BMS-946559). Clinical studies conducted so far with these ICIs revealed 
significant responses in various cancers [3]. The combination of different ICIs showed improved 
overall survival (OS) in metastatic melanoma patients. Nivolumab (targeting PD-1) combined with 
ipilimumab (targeting CTLA-4) in resulted in >80% tumor regression in 30% of patients [4]. This ICIs 
combination also showed promising results in patients with recurrent glioblastoma and advanced renal 
cell carcinoma [5]. Further, it has been reported that chemotherapy combined with ICIs (dacarbazine 
combined with ipilimumab) enhanced survival in patients with advanced melanoma in comparison to 
dacarbazine alone [6]. Unfortunately, CTLA-4 inhibitors and PD-1 and PD-L1 blocking agents can 
produce a wide range of immune-related adverse affects (IRAEs) (e.g.cardiac toxicity) [7].     
 When ICIs were introduced as cancer treatments, little attention was paid to cardiac side-
effects   ranges from asymptomatic troponin-I elevations to conduction abnormalities of the heart.  
Several cases of LV myocarditis and fatal heart failure (HF) have been reported in melanoma patients   
treated with ICIs [8-10]. Several isolated cases of fulminant myocarditis   and other cardiovascular 
disorders (pericarditis, vasculitis and AV blocks) were also reported [11-13].  Here we present a case 
of ICI-related cardio-toxicity diagnosed and managed at our hospital. 
Case Presentation   
  R.K.A, a 58-year male presented  with history of low-grade fever and  weight loss for the  
last  2 months, cough with  haemoptysis for last  3 days. On examination, his vitals were stable. On 
palpation he had diffuse cervical lymphadenopathy. Biopsy of a lymph node was done. 
Histopathology sections showed features suggestive of metastatic lesions of Renal Cell Carcinoma 
(RCC). PET-CT scan revealed the location of primary tumour to be in the left kidney with metastasis. 
Patient underwent left nephrectomy and frozen section confirmed predominant clear cell type with 
small areas also showing papillary type of RCC. ECG and 2D Echo done before surgery was normal 
with no LV/RV systolic dysfunction and normal Pulmonary artery pressure (ePASP was 15 mm of 
Hg). 
 Post-surgery, chemotherapy was initiated with oral sunitinib, a multi-targeted Receptor 
Tyrosine Kinase (RTK) inhibitor. However, he developed symptoms of dyspnoea on exertion. A high-
resolution computed tomography (HRCT) of the chest revealed nodular infiltrates in right upper as 
well as bilateral lower lung lobes. CT guided lung biopsy was done and the histology showed 
necrotizing   granulomatous inflammation. Mycobacterial infection was suspected and treatment was 
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initiated for tuberculosis with five drug AKT regimen consisting of oral isoniazid (300 mg), rifampin 
(450 mg), pyrazinamide (750 mg) and  ethambutol (800mg). Sunitinib was also continued. 
Unfortunately, there was no relief in symptoms, even after 3 cycles of sunitinib and a month on AKT 
regimen. Steroid therapy was also introduced and it leads to some improvement in symptoms. 
 After completion of 5 cycles, patient now developed extreme fatigue, diarrhea  and blood 
profile showed  severe  pancytopenia. Sunitinib was discontinued in view of these side effects. Repeat 
HRCT did show decrease in pulmonary infiltrates and lymph node (LN) size. Sunitinib was re-
introduced few weeks later, patient again developed pancytopenia. However, a month later, 
progression of disease was noticed on a PET-CT scan with cervical, mediastinal and abdominal lymph 
node involvement with deposits along multiple soft tissue planes and bones. Cytology of Pleural 
paracentesis was performed, which revealed malignant cells. AKT was stopped. 2D Echocardiogram 
was normal with no changes in pulmonary artery pressure (ePASP was 18 mm of Hg).  
 
 
 
Fig. 1 IRAE manifesting as pruritic skin rash (a: lesions on back of the patient skin; b: lesions on thigh) 
 
 Oral axitinib (small molecule tyrosine kinase inhibitor) was started in place of sunitinib and 
it lead to symptom relief and weight gain. However, the progression of disease was noticed with 
enlargement of cervical lymph nodes and only a partial mediastinal Lymph Node response was 
observed. Nivolumab (anti PD-1 monoclonal antibody) was added to low dose axitinib (2.5 mg).This 
combination lead to a dramatic response within 3 weeks and complete resolution of cervical lymph  
node involvement was noticed. However, two months later, he developed generalised  non pruritic 
skin rash (Fig 1) and the biopsy showed lymphocytic small vessel vasculitis. 2D Echo done now 
showed features of RV myocarditis with dysfunction (RVEF of 30%) with the involvement of the 
apex and free wall with pulmonary artery hypertension (PAP of 113 mm of Hg). Troponin-I was 
mildly elevateddone was normal. N-terminal pro b-type natriuretic peptide (NT-proBNP) level was 
observed to be 1150 pg/dl viral markers.  Suspecting drug toxicity, nivolumab was stopped and 
steroids were re-introduced (Table 1).  
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Table-1 Table showing progressive 2D Echocardiographic deterioration in patient on checkpoint inhibitors. 
 
Time period LV function GLS RV function ePASP  Therapy 
1).On treatment  
initiation 
60% -20 Normal Normal Axitinib 
2).At 2 months 55% -19 Normal Normal Axitinib 
3).At six months  53% -18 Normal 38 Axitinib/AKT 
4).At 8 months 55% -19% Moderate RVEF 40% RV hypokinesia 48 Axitinib/ Nivolumab 
5).At 1 year  52% -18 Moderate RVEF 30%  
RV hypokinesia 
113 Axitinib Nivolumab /  
(ePASP: estimated pulmonary artery systolic pressure [mmHg], LV: Left Ventricular. RV: Right ventricular, 
RVEF: Right ventricular ejection fraction).  
 
 
 
 
 
 
Fig. 2 FDG-PET body scan (a) showing abnormal tracer 
uptake in the right ventricular wall (black arrow). 
Proximal pulmonary artery favouring myocarditis with 
pulmonary vasculitis (b). Also, there is an evidence of 
metastatic lymphadenopathy in the abdomen (c) (black 
arrow).   
 
 Whole body FDG PET with CT scan superimposition demonstrated curvilinear high-grade 
tracer uptake along the pulmonary trunk extending to the apical and free wall of RV and proximal 
pulmonary artery favouring myocarditis with pulmonary vasculitis. Also, there is an evidence of 
metastatic lymphadenopathy in the abdomen (Fig. 2). The metastatic lesions in the liver, lungs, 
subcutaneous tissue, and skeletal system showed complete metabolic and morphologic resolution. 
There is no evidence of local recurrence in the operative bed of the left renal fossa. Improvement was 
observed in skin lesions after high dose corticosteroids. However, dyspnoea, fatigue remained 
unresponsive even after initiating treatment with ambrisentan, sildenafil, inhaled milrinone and high 
flow Oxygen. HRCT Thorax and pulmonary CT angiogram results did not reveal pulmonary 
thromboembolism or other pulmonary parenchymal lesions (Fig 3). In spite of our best efforts, 
symptoms continued to progress and the patient succumbed due to progressive right heart failure. 
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Fig. 3 HRCT thorax (a,b) and Pulmonary CT angiogram (c,d) revealed  no 
pulmonary thromboembolism or other pulmonary parenchymal lesions.  
 
Discussion  
 Modulation of the human immune system has transformed cancer therapy, and immune 
checkpoint inhibition is one of the many successful forms to treat malignancies [14]. Cancer 
immunotherapy with immune checkpoint inhibitors such as monoclonal antibodies targeting cytotoxic 
T lymphocyte associated antigen 4 or CTLA-4 and programmed cell death 1 or PD-1 and its ligand 
PD-L1, have revolutionized the treatment of many malignancies. Solid and haematological tumours 
are known to have high recurrences with poor prognosis. Immune checkpoint inhibitors (ICI) act on 
anti-tumour immunity, and can induce cancer regression, thereby improving survival in different 
cancers [8,15]. However, several case studies have unveiled a wide range of side effects from 
activation of immune system with IC’Is [8].    These side effects are more commonly referred to as 
immune-related adverse events (IRAEs) affecting skin, muscle, joints, renal, CVS, CNS, ophthalmic, 
gastrointestinal tissue and endocrine systems [12,15-17]. IRAEs are generally low grade and easily 
manageable when detected in a timely manner18.   
 Cardiotoxicity usually manifests as myocarditis with predominant left ventricular 
dysfunction. Vasculopathy can affect vessels of any size but is more common in larger vessels such as 
temporal (giant cell) arteritis or aortitis [17]. Histopathological analysis in humans has revealed 
predominant infiltration by T lymphocytes and macrophages, indicating immune complex mediated 
response as the main mechanism [12,17]. Pre-existing auto-immune diseases, co-existent cardiac 
disease or use of more than one ICI’s together can predispose patients  to cardiac toxicity [19].  
 Pulmonary vasculopathy causing pulmonary hypertension has only been described in a single 
case report, but it was also associated with left ventricular myocarditis [20]. The patient under 
discussion had rapidly progressive pulmonary hypertension. Pulmonary embolism as the cause for 
severe pulmonary hypertension was excluded by pulmonary CT angiography. Inflammation of 
pulmonary artery was confirmed on Whole body PET with CT scan superimposition, with 
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demonstration of curvilinear high-grade tracer uptake along the pulmonary trunk. Skin biopsy of 
lesions had demonstrated predominant lymphocytic small vessel vasculitis. Clinical features, skin 
histopathology and imaging (Echocardiographic and CT-PET scans) correlation indicated that 
vasculitis was most likely the cause for pulmonary hypertension.  
 2D-Echocardiography was performed at regular intervals to study the disease progression. 
The findings showed no evidence of LV dysfunction on chemotherapy. However, progressive RV 
dysfunction, attributed to RV myocarditis, was noted during the course of treatment with immune 
checkpoint inhibitors. To the best of our knowledge, this is the first report of selective RV 
involvement with cardiotoxicity attributed to immune checkpoint inhibitors, described in medical 
literature. The patient under discussion presented with predominant sub acute, progressive right 
ventricular myocarditis (confirmed on 2 D Echo and FDG PET scan) (Fig 2). Selective viral RV 
myocarditis has been described [21, 22]. According to existing consensus statements, patients with 
threatened or established vasculitis or myocarditis, ICI therapy should be immediately stopped and  
immunosuppression with other agents such as  intravenous methylprednisolone  should be commenced. 
The complex pathophysiology of RV immune-mediated myocarditis and RV dysfunction associated 
with progressive pulmonary arterial hypertension ultimately proved catastrophic.  
Conclusion 
 Although uncommon, potentially fatal cardiovascular adverse events can occur as a side 
effect of ICI. Small vessel vasculitis as a complication of ICIs has been well documented. Evidence of 
vasculitis can be in form of skin lesions. However, vasculitis involving larger vessels such as 
pulmonary artery, resulting in pulmonary hypertension is indeed rare. The combination of RV 
myocarditis with progressive pulmonary hypertension is fatal. Treatment with high dose 
corticosteroids and immunomodulators may help in   patient survival. Physicians treating patients with 
ICIs should be aware of this potentially lethal cardiotoxic side effect  and multidisciplinary approach 
is often required to reduce adverse cardiac outcome.  
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